Engineered Foxp1^high Exosomes Ameliorates Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Regenerative Medicine
• Biotechnology

Background:

• Systemic lupus erythematosus (SLE) involves immune dysregulation and impaired regulatory T cell (Treg) differentiation.
• Mesenchymal stem cell-derived exosomes (MSC-exos) show therapeutic promise for immune diseases but face challenges in production yield and organ distribution.

Purpose of the Study:

• To develop a dual-engineering strategy for MSC-exos to overcome limitations in yield and specificity for SLE treatment.
• To enhance the immunomodulatory properties and therapeutic efficacy of MSC-exos.

Main Methods:

• Developed an aggregation culture engineering strategy (Agg-exo) for high-yield MSC-exos.
• Genetically engineered MSCs to overexpress Foxp1, creating Foxp1-high Agg-exos.
• Investigated immune organ targeting and Treg promotion via the Foxp1/STAT5/Foxp3 axis.

Main Results:

• The aggregation culture strategy significantly increased exosome yield.
• Foxp1-high Agg-exos demonstrated enhanced immunomodulatory properties and superior therapeutic effects in SLE models.
• Engineered exosomes showed improved immune organ targeting and Treg promotion.

Conclusions:

• A novel dual-engineering strategy successfully produced high-yield, Foxp1-high Agg-exos.
• This approach addresses the limitations of low yield and non-specific distribution of MSC-exos.
• The engineered exosomes hold significant potential for developing exosome-based therapies for autoimmune diseases like SLE.